This is further supported by the increased expression of the anti-tumor immunity genes PDL1, CD155 (PVR), CEACAM1, LGALS9, and IDO1 (Figure 5), all of which antagonize T cell responses via their interaction with inhibitory receptors. This evidence concerns the gene PVR and neoplasm.